Viewing entries tagged
CRPC

XTANDI (enzalutamide): A New Treatment for Metastatic Castration-Resistant Prostate Cancer

Comment

XTANDI (enzalutamide): A New Treatment for Metastatic Castration-Resistant Prostate Cancer

Given enzalutamide’s unique and multi-targeted mechanism of action, its once a day oral administration, avoidance of accompanying requirement of a steroid, and its established safety and efficacy data, it appears to be a very promising therapy. Future studies should investigate both combination strategies with other approved prostate cancer drugs, as well as the potential role of enzalutamide in earlier stages of both CRPC and androgen-sensitive prostate cancer.

Comment